trifluoro-N-[4-(3-oxo-3,5-dihydro-4H-1,4,8b-triazaacenaphthylen-4-yl)butyl]methanesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并[1，2-a]吡啶
• 英文名称: trifluoro-N-[4-(3-oxo-3,5-dihydro-4H-1,4,8b-triazaacenaphthylen-4-yl)butyl]methanesulfonamide
• 英文别名: 4,5-dihydro-4-[4-(trifluoromethanesulfonamido)butan-1-yl]-3H-1,4,8b-triazaacenaphthylen-3-one；4-[4-(Trifluoromethylsulfonylamino)butyl]-4,5-dihydro-3H-1,4,8b-triazaacenaphthylene-3-one；1,1,1-trifluoro-N-[4-(5-oxo-2,6,12-triazatricyclo[6.3.1.04,12]dodeca-1,3,8,10-tetraen-6-yl)butyl]methanesulfonamide
• 化学式: C₁₄H₁₅F₃N₄O₃S
• 分子量: 376.359
• InChiKey: NWJSOYNJROTAGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  92.2
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  trifluoro-N-[4-(3-oxo-3,5-dihydro-4H-1,4,8b-triazaacenaphthylen-4-yl)butyl]methanesulfonamide 、 盐酸 以 乙醇 为溶剂， 以to leave 3.15 g of the desired compound (100%, pale yellow solid matter)的产率得到4,5-Dihydro-4-[4-(trifluoromethanesulfonamido)butan-1-yl]-3H-1,4,8b-triazaacenaphthylen-3-one-hydrochloride
  参考文献：
  名称：

  Tricyclic compounds, their production and use

  摘要：

  式子1中的三环化合物：其中环A是含有两个氮原子作为杂原子的含氮杂环，可选择性地用氧代或硫代取代; 环Q可以选择性地被取代; Y是可选择性取代的碳氢基团，可选择性取代的羟基或可选择性取代的巯基，但不包括甲基基团作为Y; R1是氢原子，卤素原子，可选择性取代的碳氢基团或酰基，或其盐，具有优异的PDGF抑制活性，降压活性，改善肾脏疾病活性和降低脂质水平活性。

  公开号：

  US20010051631A1
• 作为产物：
  描述：

  benzyl 4-{[(trifluoromethyl)sulfonyl]amino}butylcarbamate 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 6.0h， 生成 trifluoro-N-[4-(3-oxo-3,5-dihydro-4H-1,4,8b-triazaacenaphthylen-4-yl)butyl]methanesulfonamide
  参考文献：
  名称：

  A Practical Synthesis of the Chronic Renal Disease Agent, 4,5-Dihydro-3H-1,4,8b-triazaacenaphthylen-3-one Derivatives, Using Regioselective Chlorination of Ethyl 5-methylimidazo[1,2-a]pyridine-3-carboxylate with N-Chlorosuccinimide

  摘要：

  A convenient synthesis of the chronic renal disease agent, trifluoro-N-[4-(3-oxo-3,5-dihydro-4H-1,4,8b-triazaacenaphthylen-4yl)butyl]methanesulfonamide (1a), for large scale has been developed via ethyl 5-(chloromethyl)imidazo[1,2-a]pyridine-3-carboxylate (3), which was given by the regioselective chlorination of ethyl 5-methylimidazo[1,2-a]pyridine-3-carboxlate (6) with N-chlorosuccinimide (NCS) using AcOEt as a solvent in 83% yield. The condensation of 3 and primary amines gave 4,5-dihydro-3H-1,4,8b-triazaacenaphthylen-3-one derivatives (1) in good yields. The present synthesis of 1a was accomplished in five steps from 2-amino-6-methylpyridine (4) without requiring a chromatographic method. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(00)00709-2

文献信息

• ANNELATED CARBAMOYLASE-HETEROCYCLES, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE PRODUCTION THEREOF
  申请人："Chemical diversity Research Institute", Ltd.

  公开号：EP1746100A1

  公开（公告）日：2007-01-24

  This invention relates to novel annellated carbamyl-aza-heterocyclic compounds that are potential physiologically active compounds (agonists, antagonists, and receptor modulators, enzyme inhibitors, oncolytics, antibacterial and antiparasitic agents, and so on), to a focused library comprising annellated carbamyl-aza-heterocyclic compounds, a pharmaceutical composition comprising annellated carbamyl-aza-heterocyclic compounds as the active ingredient, and to methods of producing and using the same. The invention relates to annellated carbamyl-aza-heterocyclic compounds of general formula 1: wherein: W is 6-oxopiperazine, [1,4]diazepan, [1,4]thiazepan or [1,4]oxazepan compound annellated to at least one optionally substituted and optionally condensed heterocyclic compound Q; R1, R2 and R3 are, independently of one another, a hydrogen atom, an inert substituent, an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted phenyl, an optionally substituted aryl, or an optionally substituted heterocyclyl; and Q is a pyrrole, pyrazole, imidazole, thiazole, pyrrolidine, indole, benzofuran, 4,5,6,7-tetrahydrobenzothiophene, thieno[3,2-b]pyrrole, furo[3,2-b]pyrrole, thieno[2,3-b]pyrrole, benzimidazole, pyridine, quinoline, or 1,2,3,4-tetrahydroisoquinoline cyclic compound.

  本发明涉及新型的环化碳酰胺-氮杂杂环化合物，这些化合物是潜在的生理活性化合物（激动剂、拮抗剂和受体调节剂、酶抑制剂、抗肿瘤剂、抗菌和抗寄生虫剂等），还涉及一种包括环化碳酰胺-氮杂杂环化合物的焦点库、一种包括环化碳酰胺-氮杂杂环化合物作为活性成分的制药组合物，以及制备和使用这些化合物的方法。本发明涉及一般式1的环化碳酰胺-氮杂杂环化合物：其中：W是6-氧代哌嗪、[1,4]二氮杂环、[1,4]硫杂环或[1,4]噁唑杂环化合物，环化到至少一个可选取代和可选缩合的杂环化合物Q；R1、R2和R3独立地是氢原子、惰性取代基、可选取代的C1-C6烷基、可选取代的C3-C8环烷基、可选取代的苯基、可选取代的芳基或可选取代的杂环基；Q是吡咯、吡唑、咪唑、噻唑、吡咯烷、吲哚、苯并呋喃、4,5,6,7-四氢苯并噻吩、噻吩[3,2-b]吡咯、呋吒[3,2-b]吡咯、噻吩[2,3-b]吡咯、苯并咪唑、吡啶、喹啉或1,2,3,4-四氢异喹啉环化合物。
• [EN] TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE<br/>[FR] COMPOSES TRICYCLIQUES, LEUR PRODUCTION ET UTILISATION
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：WO1996002542A1

  公开（公告）日：1996-02-01

  (EN) Tricyclic compound of formula (I'), wherein ring A is a nitrogen-containing heterocyclic ring, having two nitrogen atoms as the hetero-atoms, which is optionally substituted with oxo or thioxo; ring Q may optionally be substituted; Y is an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted mecapto group, excluding for methyl group as Y; R1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group or an acyl group, or a salt thereof, having excellent PDGF-inhibiting activities, antihypertensive activities, activities of ameliorating renal diseases and activities of lowering lipil level.(FR) L'invention se rapporte à un composé tricyclique de la formule (I') dans laquelle le noyau A est un noyau hétérocyclique contenant de l'azote, et possédant deux atomes d'azote comme hétéro-atomes, et qui est éventuellement substitué par oxo ou thio; le noyau Q peut être éventuellement substitué; Y est un groupe hdyrocarbure éventuellement substitué, un groupe hdyroxyle éventuellement substitué ou un groupe mercapto éventuellement substitué, à l'exclusion d'un groupe méthyle; R1 est un atome d'hydrogène, un atome d'halogène, un groupe hydrocarbure éventuellement substituté ou un groupe acyle, ou un sel de celui-ci. Ce composé présente d'excellentes activités inhibant PDGF (facteur de croissance plaquettaire), des activités anti-hypertensives, des activités apportant une amélioration aux maladies rénales et des activités favorisant la réduction du taux lipidique.

  (I')式的三环化合物，其中环A是一个含氮杂环，具有两个氮原子作为杂原子，可以用氧代或硫代取代;环Q可以选择性地被取代;Y是一个可选择性取代的碳氢基团、可选择性取代的羟基团或可选择性取代的巯基团，不包括甲基基团作为Y;R1是一个氢原子、卤素原子、可选择性取代的碳氢基团或酰基，或其盐，具有出色的PDGF抑制活性、降压活性、改善肾脏疾病活性和降低脂质水平的活性。
• US05958942
  申请人：——

  公开号：——

  公开（公告）日：——
• TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0771319A1

  公开（公告）日：1997-05-07
• Annellated carbamyl-aza-heterocyclic compounds, a focused library, pharmaceutical compositions, and methods of preparing the same
  申请人：Ivashchenko Alexander

  公开号：US20070191337A1

  公开（公告）日：2007-08-16

  This invention relates to novel annellated carbamyl-aza-heterocyclic compounds that are potential physiologically active compounds (agonists, antagonists, and receptor modulators, enzyme inhibitors, oncolytics, antibacterial and antiparasitic agents, and so on), to a focused library comprising annellated carbamyl-aza-heterocyclic compounds, a pharmaceutical composition comprising annellated carbamyl-aza-heterocyclic compounds as the active ingredient, and to methods of producing and using the same. The invention relates to annellated carbamyl-aza-heterocyclic compounds of general formula 1: wherein: W is 6-oxopiperazine, [1,4]diazepan, [1,4]thiazepan or [1,4]oxazepan compound annellated to at least one optionally substituted and optionally condensed heterocyclic compound Q; R 1 , R 2 and R 3 are, independently of one another, a hydrogen atom, an inert substituent, an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 3 -C 8 cycloalkyl, an optionally substituted phenyl, an optionally substituted aryl, or an optionally substituted heterocyclyl; and Q is a pyrrole, pyrazole, imidazole, thiazole, pyrrolidine, indole, benzofuran, 4,5,6,7-tetrahydrobenzothiophene, thieno[3,2-b]pyrrole, furo[3,2-b]pyrrole, thieno[2,3-b]pyrrole, benzimidazole, pyridine, quinoline, or 1,2,3,4-tetrahydroisoquinoline cyclic compound.